Bystander killing effect of <scp>DS</scp>‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

Yusuke Ogitani(Daiichi Sankyo (Germany)), Toshinori Agatsuma(Daiichi Sankyo (Germany))

Cancer Science

May 11, 2016

10.1111/cas.12966

Cited by 691

Related Papers

Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models

|Molecular Cancer Therapeutics|2024|29

Novel Antibody Exerts Antitumor Effect through Downregulation of CD147 and Activation of Multiple Stress Signals

|Journal of Oncology|2022|7